US equities |
MU $983.23 ▲+5.86% META $612.49 ▼-1.24% GOOGL $324.89 ▲+1.34% NVDA $215.38 ▼-1.17% MSFT $531.01 ▼-0.06% TSLA $404.22 ▼-0.80% SPCX $145.23 ▼-2.25% SNDK $1,404.77 ▲+7.66%
FinancialContent

Geron Corporation - Common Stock (NQ:GERN)

0.9685 -0.1815 (-15.78%)
Delayed Quote Updated: 4:00 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Geron Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS
From Geron Corporation
Via Business Wire
News headline image
Geron Corporation Announces Departure of Chief Executive Officer
From Geron Corporation
Via Business Wire
News headline image
GERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Geron Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Why Geron Stock Is Plummeting Today ↗
Via The Motley Fool
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
4 Analysts Assess Geron: What You Need To Know ↗
 
Via Benzinga
News headline image
What's going on in today's session ↗
Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Dow Dips Over 100 Points; TJX Earnings Top Views ↗
 
Via Benzinga
Topics Stocks
News headline image
Here are the top movers in Wednesday's session. ↗
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Nasdaq Surges 150 Points; Lowe's Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 4 Ratings For Geron ↗
 
Via Benzinga
News headline image
Geron (GERN) Q4 2024 Earnings Call Transcript ↗
GERN earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday. 
Via Chartmill
News headline image
Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From Geron Corporation
Via Business Wire
News headline image
Geron to Participate at Upcoming Investor Conferences in March 2025
From Geron Corporation
Via Business Wire
News headline image
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
News headline image
Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
From Geron Corporation
Via Business Wire
News headline image
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
News headline image
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
News headline image
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
From Geron Corporation
Via Business Wire
News headline image
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
From Geron Corporation
Via Business Wire
News headline image
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
From Geron Corporation
Via Business Wire
News headline image
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
From Geron Corporation
Via Business Wire
News headline image
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
News headline image
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
From Geron Corporation
Via Business Wire
News headline image
Geron to Participate in the Stifel 2024 Healthcare Conference
From Geron Corporation
Via Business Wire
News headline image
Geron (GERN) Q3 2024 Earnings Call Transcript ↗
GERN earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
From Geron Corporation
Via Business Wire
News headline image
Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Geron Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >